WEST LAFAYETTE, IN--(Marketwire - January 14, 2009) - On December 24, 2008, Bioanalytical Systems, Inc. (NASDAQ: BASI) reported financial results for the three months and fiscal year ended September 30, 2008 that incorrectly stated the tax provision for the fourth quarter and fiscal year of 2008. The adjusted provision is included in the Consolidated Statements of Operations below. Net income and Earnings per Share for the fourth quarter and fiscal year 2008 for both continuing and discontinued operations have been amended to reflect this change.
For continuing operations, a net loss for the fourth quarter of fiscal 2008 was $931,000, or $0.19 per basic and diluted share, compared to net income of $208,000, or $0.04 per basic and diluted share, for the same period in fiscal 2007. For the twelve months of fiscal 2008, net income from continuing operations was $495,000, or $0.10 per basic and diluted share, compared to net income of $1.6 million, or $0.32 per basic and diluted share for fiscal 2007.
The net loss from discontinued operations was $152,000, or $0.03 per basic and diluted share, in the quarter ended September 30, 2008 compared to a net loss of $411,000, or $0.08 per basic and diluted share, in the same period last year. This resulted in a net loss from all operations in the fourth quarter of $1.1 million, or $0.22 per basic and diluted share, compared to a net loss in the same quarter of the prior fiscal year of $203,000, or $0.04 per basic and diluted share.
The net loss from discontinued operations was $2.0 million, or $0.40 per basic and diluted share, in fiscal 2008 compared to a net loss of $646,000, or $0.13 per basic and diluted share, in fiscal 2007. This resulted in a net loss from all operations in the current year of $1.5 million, or $0.30 per basic and diluted share, compared to net income in the prior year of $926,000, or $0.19 per basic and diluted share.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASInc.com for more about BASi.
This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except per share Three Months Ended Twelve Months Ended
amounts) September 30, September 30,
------------------ ------------------
2008 2007 2008 2007
-------- -------- -------- --------
Service revenue $ 7,268 $ 7,206 $ 32,921 $ 30,559
Product revenue 2,116 2,405 8,776 9,194
-------- -------- -------- --------
Total revenue 9,384 9,611 41,697 39,753
Cost of service revenue 5,593 5,039 22,941 21,676
Cost of product revenue 819 1,017 3,423 3,909
-------- -------- -------- --------
Total cost of revenue 6,412 6,056 26,364 25,585
Gross profit 2,972 3,555 15,333 14,168
Operating expenses:
Selling 1,271 745 3,912 2,782
Research and development 198 213 781 881
General and administrative 2,198 1,795 7,822 6,855
Loss on sale of property and
equipment 17 31 24 165
-------- -------- -------- --------
Total operating expenses 3,684 2,784 12,539 10,683
Operating income (loss) (712) 771 2,794 3,485
Interest income --- 35 29 87
Interest expense (304) (264) (1,006) (981)
Other income 1 (1) 6 3
-------- -------- -------- --------
Income (loss) from continuing
operations before income taxes (1,015) 541 1,823 2,594
Income taxes (benefit) (84) 333 1,328 1,022
-------- -------- -------- --------
Net income (loss) from continuing
operations $ (931) $ 208 $ 495 $ 1,572
Discontinued Operations
Loss from discontinued operations
before income taxes $ (51) $ (689) $ (2,811) $ (1,095)
Loss on disposal (43) --- (474) ---
Income taxes benefit (expense) (58) 278 1,301 449
-------- -------- -------- --------
Net income (loss) from discontinued
operations after income taxes $ (152) $ (411) $ (1,984) $ (646)
-------- -------- -------- --------
Net income (loss) $ (1,083) $ (203) $ (1,489) $ 926
======== ======== ======== ========
Basic net income (loss) per share:
Net income (loss) per share from
continuing operations $ (0.19) $ 0.04 $ 0.10 $ 0.32
Net income (loss) per share from
discontinued operations (0.03) (0.08) (0.40) (0.13)
-------- -------- -------- --------
Basic net income (loss) per
share $ (0.22) $ (0.04) $ (0.30) $ 0.19
======== ======== ======== ========
Diluted net income (loss) per
share:
Net income (loss) per share from
continuing operations $ (0.19) $ 0.04 $ 0.10 $ 0.32
Net income (loss) per share from
discontinued operations (0.03) (0.08) (0.40) (0.13)
-------- -------- -------- --------
Diluted net income (loss) per
share $ (0.22) $ (0.04) $ (0.30) $ 0.19
======== ======== ======== ========
Weighted common shares outstanding:
Basic 4,914 4,909 4,914 4,909
Diluted 4,914 4,982 4,968 4,960
